Aurinia Pharmaceuticals Stock News

Aurinia (AUPH) delivered earnings and revenue surprises of -3.85% and 9.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Aurinia (AUPH) delivered earnings and revenue surprises of -3.85% and 9.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) announces a change to the dial-in number(s) for the upcoming first quarter

Here's why three Fool.com contributors are bullish on Outset Medical, Aurinia Pharmaceuticals, and Shockwave Medical.

Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts have provided the following ratings for Aurinia Pharmaceuticals (NASDAQ:AUPH) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4

NEW YORK, March 12, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) resulting from allegations that Aurinia may have issued materially misleading business information to the investing public.

AUPH INVESTOR NOTICE:

The shares of the commercial-stage biopharmaceutical company Aurinia Pharmaceuticals <> have added more than a tenth on Wednesday to record the biggest intraday gain in over…

Over the past 3 months, 4 analysts have published their opinion on Aurinia Pharmaceuticals (NASDAQ:AUPH) stock. These analysts are typically employed by large Wall Street banks and tasked with underst

Over the past 3 months, 4 analysts have published their opinion on Aurinia Pharmaceuticals (NASDAQ: AUPH ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company''s business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 2 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 1 0 0 0 These 4 analysts have an average price target of $27.75 versus the current price of Aurinia Pharmaceuticals at $10.67, implying upside. Below is a summary of how these 4 analysts rated Aurinia … Full story available on Benzinga.com

Raymond James cut the price target on Ciena Corporation (NYSE: CIEN) from $80 to $75. Ciena shares fell 10.9% to close at $58.76 on Monday. Telsey Advisory Group cut Capri Holdings Limited (NYSE:

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) resulting from allegations that Aurinia may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Aurinia securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arr

Aurinia Pharmaceuticals (AUPH) rose 2.8% on a report that a European-based investor group is campaigning for the biotech to begin a strategic review.Aurinia holders, led…

Aurinia Pharmaceuticals, along with biotechs in general, has been beaten down recently.